Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)

Curt D. Furberg, Jackson T. Wright, Barry R. Davis, Jeffrey A. Cutler, Michael Alderman, Henry Black, William Cushman, Richard Grimm, L. Julian Haywood, Frans Leenen, Suzanne Oparil, Jeffrey Probstfield, Paul Whelton, Chuke Nwachuku, David Gordon, Michael Proschan, Paula Einhorn, Charles E. Ford, Linda B. Piller, J. Kay DunnDavid Goff, Sara Pressel, Judy Bettencourt, Barbara DeLeon, Lara M. Simpson, Joe Blanton, Therese Geraci, Sandra M. Walsh, Christine Nelson, Mahboob Rahman, Anne Juratovac, Robert Pospisil, Lillian Carroll, Sheila Sullivan, Jeanne Russo, Gail Barone, Rudy Christian, Sharon Feldman, Tracy Lucente, David Calhoun, Kim Jenkins, Peggy McDowell, Janice Johnson, Connie Kingry, Juan Alzate, Karen L. Margolis, Leslie Ann Holland-Klemme, Brenda Jaeger, Jeffrey Williamson, Gail Louis, Pamela Ragusa, Angela Williard, R. L Sue Ferguson, Joanna Tanner, John Eckfeldt, Richard Crow, John Pelosi

Research output: Contribution to journalArticlepeer-review

1143 Scopus citations


Context Studies have demonstrated that statins administered to individuals with risk factors for coronary heart disease (CHD) reduce CHD events. However, many of these studies were too small to assess all-cause mortality or outcomes in important subgroups. Objective To determine whether pravastatin compared with usual care reduces all-cause mortality in older, moderately hypercholesterolemic, hypertensive participants with at least 1 additional CHD risk factor. Design and Setting Multicenter (513 primarily community-based North American clinical centers), randomized, nonblinded trial conducted from 1994 through March 2002 in a subset of participants from the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). Participants Ambulatory persons (n=10355), aged 55 years or older, with low-density lipoprotein cholesterol (LDL-C) of 120 to 189 mg/dL (100 to 129 mg/dL if known CHD) and triglycerides lower than 350 mg/dL, were randomized to pravastatin (n=5170) or to usual care (n=5185). Baseline mean total cholesterol was 224 mg/dL; LDL-C, 146 mg/dL; high-density lipoprotein cholesterol, 48 mg/dL; and triglycerides, 152 mg/dL. Mean age was 66 years, 49% were women, 38% black and 23% Hispanic, 14% had a history of CHD, and 35% had type 2 diabetes. Intervention Pravastatin, 40 mg/d, vs usual care. Main Outcome Measures The primary outcome was all-cause mortality, with follow-up for up to 8 years. Secondary outcomes included nonfatal myocardial infarction or fatal CHD (CHD events) combined, cause-specific mortality, and cancer. Results Mean follow-up was 4.8 years. During the trial, 32% of usual care participants with and 29% without CHD started taking lipid-lowering drugs. At year 4, total cholesterol levels were reduced by 17% with pravastatin vs 8% with usual care; among the random sample who had LDL-C levels assessed, levels were reduced by 28% with pravastatin vs 11% with usual care. All-cause mortality was similar for the 2 groups (relative risk [RR], 0.99; 95% confidence interval [CI], 0.89-1.11; P=.88), with 6-year mortality rates of 14.9% for pravastatin vs 15.3% with usual care. CHD event rates were not significantly different between the groups (RR, 0.91; 95% CI, 0.79-1.04; P=.16), with 6-year CHD event rates of 9.3% for pravastatin and 10.4% for usual care. Conclusions Pravastatin did not reduce either all-cause mortality or CHD significantly when compared with usual care in older participants with well-controlled hypertension and moderately elevated LDL-C. The results may be due to the modest differential in total cholesterol (9.6%) and LDL-C (16.7%) between pravastatin and usual care compared with prior statin trials supporting cardiovascular disease prevention.

Original languageEnglish (US)
Pages (from-to)2998-3007
Number of pages10
JournalJournal of the American Medical Association
Issue number23
StatePublished - Dec 18 2002

Fingerprint Dive into the research topics of 'Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT-LLT)'. Together they form a unique fingerprint.

Cite this